Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective

References

• Moorman AV, Chilton L, Wilkinson J, et al. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood 2010;115:206-14
   PubMed Web of Science ®Google Scholar
• Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007;109:944-50
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, O’Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004;101:2788-801
   PubMed Web of Science ®Google Scholar
• Oriol A, Vives S, Hernandez-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica 2010;95:589-96
   PubMed Web of Science ®Google Scholar
• Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005;106:3760-7
   PubMed Web of Science ®Google Scholar
• Tabor EE, Waddell JA, Solimando DA Jr. Blinatumomab and pembrolizumab. Hosp Pharm 2015;50:269-73
   PubMedGoogle Scholar
• Geyer MB, Hsu M, Devlin SM, et al. Overall survival among older U.S. adults with ALL remains low despite modest improvement since 1980: SEER analysis. Blood 2017;129:1878-81
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Kelsh M, Chia V, et al. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J 2016;6:e473
   PubMed Web of Science ®Google Scholar
• Katz AJ, Chia VM, Schoonen WM, et al. Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden. Cancer Causes Control 2015;26:1627-42
   PubMed Web of Science ®Google Scholar
• Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2015;16:57-66
   PubMed Web of Science ®Google Scholar
• NCCN. Clinical practice guidelines in oncology for acute lymphoblastic leukemia, Version 1.2017. http://www.nccn.org/professionals/physician_gls/pdf/all.pdf. Accessed June 28, 2017
   Google Scholar
• Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 2017;376:836-47
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Dombret H, Ribera JM, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica 2016;101:1524-33
   PubMed Web of Science ®Google Scholar
• Dombret H, Topp MS, Schuh A, Wei A, Martinelli G, Durrant S, Larry Bacon C, Nie K, Zimmerman Z, Kantarjian H. Blinatumomab vs SOC chemotherapy in first salvage compared with second or greater salvage in a phase 3 study. EHA Learning Center. Jun 24, 2017. Abstract S478
   Google Scholar
• Topp M, Zimmerman Z, Cannell P, et al. Health-related quality of life (HRQoL) of blinatumomab versus standard of care (SOC) chemotherapy in patients with relapsed or refractory Philadelphia negative B-cell precursor acute lymphoblastic leukemia in a randomized, open-label phase 3 study (TOWER). Oral presentation at ASH 58th Annual Meeting & Exposition. San Diego, CA. December 3, 2016
   Google Scholar
• Nanavaty M, Kaura S, Mwamburi M, et al. The use of incremental cost-effectiveness ratio thresholds in health technology assessment decisions. J Clin Pathways 2015;1:29-36
   Google Scholar
• Aldy J, Viscusi W. Adjusting the value of a statistical life for age and cohort effects. Rev Econ Stat 2008;90:573-81
   Web of Science ®Google Scholar
• Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist 2006;11:90-5
   PubMed Web of Science ®Google Scholar
• Ubel PA, Berry SR, Nadler E, et al. In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survival. Health Aff (Millwood) 2012;31:709-17
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Campioni M, Benedict A, et al. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. J Med Econ 2016;19:1061-74
   PubMed Web of Science ®Google Scholar
• Stopeck A, Rader M, Henry D, et al. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ 2012;15:712-23
   PubMedGoogle Scholar
• Jackson C. Package ‘flexsurv’. Flexible parametric survival and multi-state models. 2016. https://cran.r-project.org/web/packages/flexsurv/flexsurv.pdf. Accessed January 30, 2016
   Google Scholar
• Bagust A, Beale S. Survival analysis and extrapolation modeling of time-to-event clinical trial data for economic evaluation: an alternative approach. Med Decis Making 2014;34:343-51
   PubMed Web of Science ®Google Scholar
• Rowen D, Brazier J, Young T, et al. Deriving a preference-based measure for cancer using the EORTC QLQ-C30. Value Health 2011;14:721-31
   PubMed Web of Science ®Google Scholar
• Mehta J, Powles R, Singhal S, et al. Autologous bone marrow transplantation for acute myeloid leukemia in first remission: identification of modifiable prognostic factors. Bone Marrow Transplant 1995;16:499-506
   PubMed Web of Science ®Google Scholar
• Mehta J, Powles R, Treleaven J, et al. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine. Bone Marrow Transplant 1996;18:741-6
   PubMed Web of Science ®Google Scholar
• Powles R, Mehta J, Singhal S, et al. Autologous bone marrow or peripheral blood stem cell transplantation followed by maintenance chemotherapy for adult acute lymphoblastic leukemia in first remission: 50 cases from a single center. Bone Marrow Transplant 1995;16:241-7
   PubMed Web of Science ®Google Scholar
• Singhal S, Powles R, Treleaven J, et al. Long-term outcome of adult acute leukemia patients who are alive and well two years after allogeneic bone marrow transplantation from an HLA-identical sibling. Leuk Lymphoma 1999;34:287-94
   PubMed Web of Science ®Google Scholar
• Singhal S, Powles R, Treleaven J, et al. Long-term outcome of adult acute leukemia patients who are alive and well 2 years after autologous blood or marrow transplantation. Bone Marrow Transplant 1999;23:875-9
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006;26:410-20.
   PubMed Web of Science ®Google Scholar
• Truven Heath Analytics. Red Book. 2016. http://micromedex.com/products/product-suites/clinical-knowledge/redbook. Accessed September 26, 2016
   Google Scholar
• Barlev A, Lin VW, Song X. Burden of hospitalization in relapsed acute lymphoblastic leukemia. Curr Med Res Opin 2016;32:1209-12
   PubMed Web of Science ®Google Scholar
• Blue Cross and Blue Shield of Michigan. Medicare advantage PPO enhanced benefits. Fee schedule. Revised July 1, 2016. https://www.bcbsm.com/content/dam/public/Providers/Documents/help/medicare-advantage-fee-schedule.pdf. Accessed September 26, 2016
   Google Scholar
• Center for Medicare and Medicaid Services. 2016. Physician fee schedule search. https://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx. Accessed September 26, 2016
   Google Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second panel on cost-Effectiveness in health and medicine. JAMA 2016;316:1093-103
   PubMed Web of Science ®Google Scholar
• Laska EM, Meisner M, Siegel C, et al. Ratio-based and net benefit-based approaches to health care resource allocation: proofs of optimality and equivalence. Health Econ 1999;8:171-4
   PubMed Web of Science ®Google Scholar
• Hillner BE, Schrag D, Sargent DJ, et al. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. Cancer 2005;104:1871-84
   PubMed Web of Science ®Google Scholar
• Chastek B, Harley C, Kallich J, et al. Health care costs for patients with cancer at the end of life. J Oncol Pract 2012;8:75s-80s
   PubMedGoogle Scholar